3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 4
1
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Anemia
2
Pancreatic Neoplasms
1
Neoplasms
1
Lymphoproliferative Disorders
1
Liver Neoplasms
1
Inflammatory Breast Neoplasms
1
Carcinoma, Ductal, Breast
1
Cancer Anaemia
1
Aortic Aneurysm
1
Anemia, Iron-Deficiency
1
Advanced Gastric Carcinoma
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Prednisone
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
atezolizumab
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
ferric carboxymaltose
×
Clear all
NCT02453334
2021-05-11
IRON CLAD
American Regent, Inc.
Phase 3
Completed
244 enrolled
33 charts